Будь ласка, використовуйте цей ідентифікатор, щоб цитувати або посилатися на цей матеріал: http://ir.librarynmu.com/handle/123456789/241
Повний запис метаданих
Поле DCЗначенняМова
dc.contributor.authorKyriachenko, Y.-
dc.contributor.authorFalalyeyeva, T.-
dc.contributor.authorKorotkyi, O.-
dc.contributor.authorMolochek, N.-
dc.contributor.authorKobyliak, N.-
dc.date.accessioned2019-11-30T22:06:47Z-
dc.date.available2019-11-30T22:06:47Z-
dc.date.issued2019-03-15-
dc.identifier.issn10.4239/wjd.v10.i3.154.-
dc.identifier.urihttp://ir.librarynmu.com/handle/123456789/241-
dc.description.abstractType 2 diabetes (T2D) is a disorder characterized by chronic inflated blood glucose levels (hyperglycemia), at first due to insulin resistance and unregulated insulin secretion but with tendency towards global spreading. The gut microbiota is recognized to have an influence on T2D, although surveys have not formed a clear overview to date. Because of the interactions between gut microbiota and host homeostasis, intestinal bacteria are believed to play a large role in various diseases, including metabolic syndrome, obesity and associated disease. In this review, we highlight the animal and human studies which have elucidated the roles of metformin, α-glucosidase inhibitors, glucagon-like peptide-1 agonists, peroxisome proliferator-activated receptors γ agonists, inhibitors of dipeptidyl peptidase-4, sodium/glucose cotransporter inhibitors, and other less studied medications on gut microbiota. This review is dedicated to one of the most widespread diseases, T2D, and the currently used antidiabetic drugs and most promising new findings. In general, the gut microbiota has been shown to have an influence on host metabolism, food consumption, satiety, glucose homoeostasis, and weight gain. Altered intestinal microbiota composition has been noticed in cardiovascular diseases, colon cancer, rheumatoid arthritis, T2D, and obesity. Therefore, the main effect of antidiabetic drugs is on the microbiome composition, basically increasing the short-chain fatty acids-producing bacteria, responsible for losing weight and suppressing inflammation.uk_UA
dc.language.isoenuk_UA
dc.publisherBaishideng Publishing Groupuk_UA
dc.relation.ispartofseriesWorld Journal of Diabetes;10(3):154-168.-
dc.subjectα-glucosidase inhibitorsuk_UA
dc.subjectType 2 diabetesuk_UA
dc.subjectDipeptidyl peptidase-4 inhibitorsuk_UA
dc.subjectGlucagon-like peptide-1 agonistsuk_UA
dc.subjectGut microbiotauk_UA
dc.subjectMetforminuk_UA
dc.subjectPeroxisome proliferator-activated receptors γ agonistsuk_UA
dc.subjectSodium/glucose cotransporter inhibitorsuk_UA
dc.titleCrosstalk between gut microbiota and antidiabetic drug actionuk_UA
dc.typeArticleuk_UA
Розташовується у зібраннях:Наукові публікації кафедри ендокринології

Файли цього матеріалу:
Файл Опис РозмірФормат 
WJD-10-154.pdf1,71 MBAdobe PDFЕскіз
Переглянути/Відкрити


Усі матеріали в архіві електронних ресурсів захищені авторським правом, всі права збережені.